middle.news
Actinogen strengthens cash position before Alzheimer’s trial results
2:16pm on Monday 26th of October, 2026 AEDT
•
Biotechnology
Read Story
Actinogen strengthens cash position before Alzheimer’s trial results
2:16pm on Monday 26th of October, 2026 AEDT
Key Points
A$10.84 million FY2026 R&D tax incentive rebate received
A$5.99 million net cash proceeds after repaying Endpoints Capital
A$21.9 million pro forma quarter-end cash position
No debt following repayment of the A$4.3 million advance
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE